



## ASX ANNOUNCEMENT

### **Starpharma SPP closes heavily oversubscribed; completing \$35m financing**

**Melbourne, Australia; 8 December, 2011:** Starpharma (ASX: SPL; OCTQX: SPHRY) today announced that its Share Purchase Plan (SPP) which closed on Wednesday 7 December 2011, is oversubscribed by more than 400%. The SPP was capped at \$3 million, and shareholders have subscribed a total in excess of \$12 million.

The SPP follows a placement in November to international and domestic institutional, sophisticated and professional investors which raised A\$32 million. The SPP and placement were conducted at the last closing price prior to Trading Halt on 14 November (A\$1.075 per share). There was strong participation in the placement from existing investors and it was led by the large UK based global fund M&G, which acquired a 6.7% stake in the Company,

As a result of the strong demand and oversubscription of the SPP, applications will need to be scaled back, and refunds will be issued following allotment of the new shares.

Starpharma Chief Executive Officer Dr Jackie Fairley said: "We are delighted to see such strong demand shown in the recent financing and we thank our shareholders for their tremendous support. These funds will allow us to significantly accelerate multiple products based on our dendrimer technology platform and position the company very strongly for the future."

The total funding of A\$35m will be largely directed towards advancing the following applications for Starpharma's technology:

- **Bacterial Vaginosis:** The development of VivaGel<sup>®</sup> for BV is now funded through to registration for two applications and will capture a share of markets estimated to be worth in excess of A\$1.3 billion for the prevention and recurrence indications. Starpharma expects to commence pivotal Phase 3 clinical trials early next year.
- **Drug Delivery:** Starpharma's internal drug delivery program includes improvement of Docetaxel, a powerful and widely used chemotherapeutic drug with sales of A\$3 billion in 2010. This funding will allow Starpharma to advance development of a dendrimer reformulation of the drug, potentially improving the side effect profile and patient outcomes, to a stage where it can command significant commercial value via a partnership. Investigatory and preclinical work with other drugs also continues.
- **Agrochemicals:** Starpharma's lead candidate in its internal agrochemical program is an enhanced reformulation of the A\$5 billion herbicide Glyphosate (RoundUp<sup>®</sup>). New funding will be directed towards accelerating an improved Glyphosate formulation program as well as advancing a solvent reduced/free agrochemical formulation and a number of other selected agrochemical agents.

## ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KGaA.

The Company's lead pharmaceutical development product is VivaGel<sup>®</sup> (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV, genital herpes and bacterial vaginosis. Starpharma has a licence agreement with Ansell Limited to develop a VivaGel<sup>®</sup>-coated condom, and a licence agreement with Okamoto Industries Inc in relation to the VivaGel<sup>®</sup>-coated condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

Starpharma also has agreements in place with Lilly, Elanco, Stiefel Laboratories (a GSK Company), and Siemens Healthcare as well as many research collaborations with some of the world's leading organisations in the fields of pharmaceuticals, drug delivery, cosmetics and agrochemicals.

A dendrimer is a type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

**American Depository Receipts (ADRs):** Starpharma's ADRs trade under the code **SPHRY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). Starpharma's ADRs are listed on International OTCQX, a premium market tier in the U.S. for international exchange-listed companies.

## FOR FURTHER INFORMATION

### Media:

#### **Buchan Consulting**

Rebecca Wilson

Mob: +61 417 382 391

[rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

Haley Price

Mob: +61 423 139 163

[hprice@buchanwe.com.au](mailto:hprice@buchanwe.com.au)

### Starpharma:

Dr Jackie Fairley, Chief Executive Officer

+61 3 8532 2704

Ben Rogers, Company Secretary

+61 3 8532 2702

[ben.rogers@starpharma.com](mailto:ben.rogers@starpharma.com)

[www.starpharma.com](http://www.starpharma.com)

## Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.